Akcea Therapeutics Inc (AKCA) Gross Profit Margin starting from the second quarter 2020 to second quarter 2019, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Akcea Therapeutics Inc   (NASDAQ: AKCA)


Akcea Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKCA Gross Profit Margin (Jun 30 2020)
Q2 		(Mar 31 2020)
Q1 		(Dec 31 2019)
Q4 		(Sep 30 2019)
Q3 		(Jun 30 2019)
Q2
Y / Y Revenue Change -15.95 %
Seq. Revenue Change 39.21 %
Revenue In Millions $22.38
Gross Profit Margin 93.66 %
Gross Profit Margin Total Ranking # 171
Gross Profit In Millions $20.96
Y / Y Gross Profit Change 0.57 %
Seq. Gross Profit Change 85.63 %


Commenting Second Quarter 2020 Gross Profit Margin
Akcea Therapeutics Inc Gross Profit grew by 85.63 % in Q2 sequentially to 21 millions, while Revenue increased by 39.21 %, this led to improvement in the company's Gross Profit Margin to 93.66 %, above the Akcea Therapeutics Inc average Gross Profit Margin.


Observing second quarter 2020 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 171, from total ranking in the previous quarter at 831.
Learn about Gross Margin
AKCA's Gross Profit Margin second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 34
Overall # 163

Gross Profit Margin Statistics
High Average Low
99.48 % 88.09 % 70.24 %
(Dec 31 2019)   (Mar 31 2020)


AKCA Gross Income Trends • More of AKCA's Profitabilty Ratios • AKCA Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
AKCA's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
AKCA's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for AKCA's Competitors
Gross Profit Margin Profit Margin for Akcea Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for AKCA's Customers

You may also want to know
AKCA's Annual Growth Rates AKCA's Profitability Ratios AKCA's Asset Turnover Ratio AKCA's Dividend Growth
AKCA's Roe AKCA's Valuation Ratios AKCA's Financial Strength Ratios AKCA's Gross Profit Growth
AKCA's Roa AKCA's Inventory Turnover Ratio AKCA's Growth Rates AKCA's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2020 MRQ Gross ProfitJun 30 2020 MRQ Revenue
REGENEREX PHARMA, INC.  100.00 %$ 0.000  Millions$ 0.000  Millions
Deciphera Pharmaceuticals Inc   99.89 %$ 7.082  Millions$ 7.090  Millions
Lite Strategy Inc   99.61 %$ 25.405  Millions$ 25.504  Millions
Kindred Biosciences Inc   99.08 %$ 39.204  Millions$ 39.567  Millions
Omeros Corporation  98.91 %$ 13.383  Millions$ 13.530  Millions
Global Blood Therapeutics Inc.  98.80 %$ 31.124  Millions$ 31.501  Millions
Edesa Biotech Inc   98.66 %$ 0.109  Millions$ 0.110  Millions
Corcept Therapeutics Inc  98.61 %$ 87.331  Millions$ 88.565  Millions
Rigel Pharmaceuticals Inc  98.26 %$ 15.742  Millions$ 16.021  Millions
Agios Pharmaceuticals Inc   98.19 %$ 36.672  Millions$ 37.347  Millions
Vyne Therapeutics Inc   98.15 %$ 11.472  Millions$ 11.688  Millions
Adamas Pharmaceuticals Inc  97.97 %$ 18.413  Millions$ 18.794  Millions
Ionis Pharmaceuticals Inc   97.93 %$ 142.525  Millions$ 145.537  Millions
Intercept Pharmaceuticals inc   97.57 %$ 75.372  Millions$ 77.249  Millions
Acadia Pharmaceuticals Inc   97.37 %$ 107.204  Millions$ 110.103  Millions
Ultragenyx Pharmaceutical Inc   97.08 %$ 59.906  Millions$ 61.709  Millions
Travere Therapeutics Inc   96.92 %$ 46.936  Millions$ 48.430  Millions
Durect Corp  96.27 %$ 24.880  Millions$ 25.844  Millions
Strongbridge Biopharma plc  94.94 %$ 7.367  Millions$ 7.760  Millions
Regeneron Pharmaceuticals Inc   94.75 %$ 1,849.500  Millions$ 1,952.000  Millions
Jazz Pharmaceuticals Plc  94.27 %$ 530.195  Millions$ 562.436  Millions
Avalo Therapeutics Inc   94.20 %$ 1.260  Millions$ 1.338  Millions
Akcea Therapeutics Inc   93.66 %$ 20.959  Millions$ 22.377  Millions
Supernus Pharmaceuticals inc   93.38 %$ 118.343  Millions$ 126.729  Millions
United Therapeutics Corporation  92.85 %$ 336.100  Millions$ 362.000  Millions
Gw Pharmaceuticals Plc  92.82 %$ 112.589  Millions$ 121.297  Millions
Dynavax Technologies Corporation  92.50 %$ 2.468  Millions$ 2.668  Millions
Ardelyx inc   92.32 %$ 1.695  Millions$ 1.836  Millions
Lexicon Pharmaceuticals Inc   92.06 %$ 8.435  Millions$ 9.163  Millions
Ocular Therapeutix Inc   91.46 %$ 1.435  Millions$ 1.569  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.